Adult-onset Still’s disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept

References

• Bywaters EG. Still�s disease in the adult. Ann Rheum Dis. 1971;30:121�33.
   Google Scholar
• Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult Still's disease: review of 228 cases from the literature. J Rheu-matol. 1987;14: 1139–46.
   Google Scholar
• Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima
   Google Scholar
• Kahn MF. Adult Still's disease. Still many issues unresolved. J Rheumatol. 1996;23:2015–6.
   Google Scholar
• Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis. 2006;65:564–72.
   PubMed Web of Science ®Google Scholar
• Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, et al. Reactive haemophagocytic syndrome in adult-onset Still�s disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65:1596�601.
   Web of Science ®Google Scholar
• Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford). 2008;47:1686�91.
   Web of Science ®Google Scholar
• Hot A, Toh ML, Coppere B, Perard L, Madoux MH, Mausservey C, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine (Baltimore). 2010;89:37�46.
   Web of Science ®Google Scholar
• Wong KF, Hui PK, Chan JK, Chan YW, Ha SY. The acute lupus hemophagocytic syndrome. Ann Intern Med. 1991;114:387–90.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still�s disease. J Rheumatol. 1992;19:424�30.
   Web of Science ®Google Scholar
• Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH,
   Google Scholar
• Maeshima K, Ishu K, Horita M, Hamasaki H, Abe I, Moriyama
   Google Scholar
• Bambery P, Thomas RJ, Malhotra HS, Kaur U, Bhusnurmath SR,
   Google Scholar
• Fautrel B, Borget C, Rozenberg S, Meyer 0, Le Loet X, Masson C, et al. Corticosteroid sparing effect of low dose methotrexate
   Google Scholar
• Fujii T, Akizuki M, Kameda H, Matsumura M, Hirakata M, Yoshida T, et al. Methotrexate treatment in patients with adult
   Google Scholar
• Cavagna L, Caporali R, Epis 0, Bobbio-Pallavicini F, Monte-cucco C. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol.
   Google Scholar
• Kokkinos A, Iliopoulos A, Greka P, Efthymiou A, Katsilambros N, Sfikakis PP. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol. 2004;23:45–9.
   Google Scholar
• Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum. 2002;46:1171–6.
   PubMed Web of Science ®Google Scholar
• Kumari R, Uppal SS. Prolonged remission in adult-onset Still's disease with etanercept. Clin Rheumatol. 2006;25:106–8.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–6.
   PubMed Web of Science ®Google Scholar
• Pain CE, McCann U. Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics. 2009;3:127–39.
   PubMedGoogle Scholar
• van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheuma-toid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Symmons DP, Watson KD, Silman AJ. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:1786–94.
   PubMed Web of Science ®Google Scholar
• Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Eta-nercept in the treatment of macrophage activation syndrome. J Rheumatol. 2001;28:2120–4.
   Google Scholar
• Cortis E, Insalaco A. Macrophage activation syndrome in juve-nile idiopathic arthritis. Acta Paediatr Suppl. 2006;95:38–41.
   PubMedGoogle Scholar
• Makay B, Yilmaz S, Turkyilmaz Z, Unal N, Oren H, Unsal E. Etanercept for therapy-resistant macrophage activation syn-drome. Pediatr Blood Cancer. 2008;50:419–21.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30:401–3.
   PubMed Web of Science ®Google Scholar
• Stem A, Riley R, Buckley L. Worsening of macrophage activa-tion syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. J Clin Rheumatol. 2001;7:252–6.
   Google Scholar
• Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 2002;46:3388–9.
   PubMed Web of Science ®Google Scholar
• Perdan-Pirkmajer K, Praprotnik S, Tomgi6 M. A case of refrac-tory adult-onset Still's disease successfully controlled with toc-ilizumab and a review of the literature. Clinical Rheumatol. 2010;29:1465–7.
   Google Scholar
• Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92–6.
   Google Scholar
• Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad 0, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67: 302–8.
   Google Scholar
• Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52:1794–803.
   Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371:998–1006.
   PubMed Web of Science ®Google Scholar
• Aouba A, De Bandt M, Aslangul E, Atkhen N, Patri B. Hae-mophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford). 2003;42:800–2.
   PubMed Web of Science ®Google Scholar